Effect of food on the pharmacokinetics and pharmacodynamics of an oral ghrelin agonist (ARD-07) in healthy subjects

Journal of Clinical Pharmacology

Volumn 49, Issue 5, 2009, Pages 553-559

  MacLean, Carol M ^b   Casanova, Anna Tina ^a   Baselgia Jeker, Luisa ^a   Neave, Nicola ^b   Larsen, Finn ^b   Skillern, Laurence ^b   Drewe, Juergen ^a   Beglinger, Christoph ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b Ardana   (France)

Author keywords

Ghrelin; Growth hormone; Humans; Pharmacodynamics; Pharmacokinetics

Indexed keywords

2 METHYLALANYL DEXTRO TRYPTOPHAN 1 FORMAMIDO 2 (3 INDOLYL)ETHYLAMIDE; ARD 07; GHRELIN AGONIST; GROWTH HORMONE; PEPTIDE DERIVATIVE; PEPTIDOMIMETIC AGENT; SOMATOMEDIN C; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOASSAY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG TOLERABILITY; FEMALE; FOOD; FOOD DRUG INTERACTION; GROWTH HORMONE BLOOD LEVEL; GROWTH HORMONE RELEASE; HEADACHE; HUMAN; MALE; MEAL; NORMAL HUMAN; PHARMACODYNAMICS; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SCANNING ELECTRON MICROSCOPY; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, ORAL; ADULT; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOOD-DRUG INTERACTIONS; GHRELIN; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; OLIGOPEPTIDES;

EID: 65449159737     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270008330160     Document Type: Article

References (23)

1. Broglio F., Arvat E., Gottero C., et al. Natural and synthetic growth hormone secretagogues: do they have therapeutic potential ? Treat Endocrinol. 2003 ; 2: 153-163. (Pubitemid 36849581)
2. Piccoli F., Degen L., MacLean C., et al. Pharmacokinetics and pharmacodynamic effects of an oral ghrelin agonist in healthy subjects. J Clin Endocrinol Metab. 2007 ; 92: 1814-1820. (Pubitemid 46997194)
3. Nagaya N., Kojima M., Uematsu M., et al. Hemodynamic and hormonal effects of human ghrelin in healthy volunteers. Am J Physiol Regul Integr Comp Physiol. 2001 ; 280: R1483 - R1487. (Pubitemid 32436103)
4. Nagaya N., Uematsu M., Kojima M., et al. Chronic administration of ghrelin improves left ventricular dysfunction and attenuates development of cardiac cachexia in rats with heart failure. Circulation. 2001 ; 104: 1430-1435. (Pubitemid 32880158)
5. Wren AM, Seal LJ, Cohen MA, et al. Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab. 2001 ; 86: 5992.
6. Neary NM, Small CJ, Wren AM, et al. Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial. J Clin Endocrinol Metab. 2004 ; 89: 2832-2836. (Pubitemid 38766373)
7. Trudel L., Tomasetto C., Rio MC, et al. Ghrelin/motilin-related peptide is a potent prokinetic to reverse gastric postoperative ileus in rat. Am J Physiol Gastrointest Liver Physiol. 2002 ; 282: G948 - G952. (Pubitemid 34651600)
8. rskov H., Frystyk J., Nielsen C., Hansen AT, Weeke J., Jørgensen JO Concomitant, specific determination of growth hormone and pegvisomant in human serum. Growth Horm IGF Res. 2007 ; 17: 431-434. (Pubitemid 47324308)
9. Frystyk J., Dinesen B., Orskov H. Non-competitive time-resolved immunofluorometric assays for determination of human insulin-like growth factor I and II. Growth Regul. 1995 ; 5: 169-176. (Pubitemid 26018330)
10. Cryer PE Glucose homeostasis and hypoglycemia. In: Wilson JD, Foster DW, eds. Williams Textbook of Endocrinology. Philadelphia: Saunders ; 1992: 1223-1228.
11. Bernkop-Schnurch A., Walker G. Multifunctional matrices for oral peptide delivery. Crit Rev Ther Drug Carrier Syst. 2001 ; 18: 459-501 (Pubitemid 33117496)
12. Gomez-Orellana I. Strategies to improve oral drug bioavailability. Expert Opin Drug Deliv. 2005 ; 2: 419-433. (Pubitemid 41683218)
13. Donovan MD, Flynn GL, Amidon GL Absorption of polyethylene glycols 600 through 2000: the molecular weight dependence of gastrointestinal and nasal absorption. Pharm Res. 1990 ; 7: 863-868. (Pubitemid 20332540)
14. Donovan MD, Flynn GL, Amidon GL The molecular weight dependence of nasal absorption: the effect of absorption enhancers. Pharm Res. 1990 ; 7: 808-815. (Pubitemid 20332532)
15. Woodley JF Enzymatic barriers for GI peptide and protein delivery. Crit Rev Ther Drug Carrier Syst. 1994 ; 11: 61-95.
16. Fix JA Strategies for delivery of peptides utilizing absorption-enhancing agents. J Pharm Sci. 1996 ; 85: 1282-1285. (Pubitemid 27014180)
17. Goldberg M., Gomez-Orellana I. Challenges for the oral delivery of macromolecules. Nat Rev Drug Discov. 2003 ; 2: 289-295. (Pubitemid 37361687)
18. Buclin T., Cosma Rochat M., Burckhardt P., Azria M., Attinger M. Bioavailability and biological efficacy of a new oral formulation of salmon calcitonin in healthy volunteers. J Bone Miner Res. 2002 ; 17: 1478-1485.
19. Tozaki H., Emi Y., Horisaka E., Fujita T., Yamamoto A., Muranishi S. Degradation of insulin and calcitonin and their protection by various protease inhibitors in rat caecal contents: implications in peptide delivery to the colon. J Pharm Pharmacol. 1997 ; 49: 164-168. (Pubitemid 27096110)
20. Tozaki H., Komoike J., Tada C., et al. Chitosan capsules for colon-specific drug delivery: improvement of insulin absorption from the rat colon. J Pharm Sci. 1997 ; 86: 1016-1021. (Pubitemid 27382903)
21. Arbit E., Goldberg M., Gomez-Orellana I., Majuru S. Oral heparin: status review. Thromb J. 2006 ; 4: 6. (Pubitemid 44177268)
22. Mousa S., Zhang F., Aljada A., et al. Pharmacokinetics and pharmacodynamics of oral heparin solid dosage form in healthy human subjects. J Clin Pharmacol. 2007 ; 47: 1508-1520. (Pubitemid 350115298)
23. Beglinger C., Poller B., Arber E., et al. Pharmacokinetics and pharmacodynamic effects of oral GLP-1 and PYY3-36: a proof of concept study in healthy subjects. Clin Pharmacol Ther. 2008 ; 84: 468-474.